Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020

Date: October 22, 2011
Pages: 26
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E34935C9D7EEN

Download PDF Leaflet

Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020


GlobalData’s pharmaceuticals report, “Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020” provides Erbitux sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Non-Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Erbitux including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of the drug including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Erbitux in each of the seven major markets

Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1.1 List of Tables
1.2 List of Figures


2.1 NSCLC Market
2.2 Epidemiology
2.3 Etiology
  2.3.1 Tobacco
  2.3.2 Radon
  2.3.3 Asbestos
  2.3.4 Other Environmental Agents
2.4 GlobalData Report Guidance


3.1 NSCLC Disease Market
3.2 NSCLC Disease Market Forecasts and CAGR
3.3 Drivers for the NSCLC Disease Market
  3.3.1 High Incidence
  3.3.2 High Mortality Rate
  3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC
  3.3.4 Emergence of Targeted Drugs and Maintenance Therapy
  3.3.5 Promising Pipeline Drugs



5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Approval History of Erbitux
5.5 Factors Affecting Sales of Erbitux
  5.5.1 NSCLC Market
  5.5.2 Mechanism of action
  5.5.3 High overall survival
  5.5.4 Uncertainty with respect to its approval in EU
  5.5.5 Approval in the US
  5.5.6 Cost-benefit trade-off
  5.5.7 Presence in Market Prior to NSCLC market approval
5.6 Drug Risk Benefit Score
  5.6.1 Efficacy
  5.6.2 Safety
  5.6.3 Compliance
  5.6.4 Dosing Convenience
5.7 Intensity of Competition
5.8 Sales forecast
  5.8.1 Target patient Pool of Erbitux
  5.8.2 Dosing
  5.8.3 Market Penetration
  5.8.4 Annual Cost of Therapy
  5.8.5 Sales Projections of Erbitux


6.1 Market Definitions
6.2 List of Abberiviations
6.3 Research Methodology
  6.3.1 Coverage
  6.3.2 Secondary Research
  6.3.3 Forecasting
  6.3.4 Number of Patients Approved to take the Drug
  6.3.5 Net Penetration of Drug
  6.3.6 Net Annual Dosing
  6.3.7 Annual Cost of Therapy
  6.3.8 Primary Research
  6.3.9 Expert Panels
6.4 Contact Us
6.5 Disclaimer
6.6 Sources


Table 1: NSCLC, Incidences and Mortality, 2008–2030
Table 2: NSCLC, Global, Market Size Forecast ($bn), 2009–2020
Table 3: Clinical Trial Results (first-line treatment)
Table 4: Approval History of Erbitux
Table 5: Drug Risk Benefit Score of Erbitux
Table 6: Annual Cost of Therapy, The US
Table 7: NSCLC, The US, Estimated Sales for Erbitux ($m), 2013–2020


Figure 1: Percentage Distribution of Top 20 Cancers
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008
Figure 4: % Share of Risk Factors in Developed Countries
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 2009–2020
Figure 7: NSCLC, Global, Incidence (in millions), 2008-2030
Figure 8: Oncology, Global, Incidence (in millions), 2008-2030
Figure 9: Broad Classification of NSCLC
Figure 10: Detailed TNM Classification
Figure 11: Classification of NSCLC
Figure 12: Drug Model Diagram of Erbitux
Figure 13: NSCLC, The US, Estimated Sales for Erbitux ($m), 2013–2020
Figure 14: GlobalData Methodology
Figure 15: Drug Model Diagram
Figure 16: Patients Approved for the Drug
Skip to top

Ask Your Question

Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: